Melissa Fazzari

Melissa Fazzari

Auto-generated profile, based on publicly available information

Melissa Fazzari

Department of Epidemiology & Population Health, Bronx NYAlbert Einstein College of Medicine Bronx New York USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1999 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DBDean F. Bajorin
Dean F. Bajorin
PDPaul M. Dodd
Paul M. Dodd
MMMadhu Mazumdar
Madhu Mazumdar
MFMelissa Fazzari
Melissa Fazzari
JMJohn A. McCaffrey
John A. McCaffrey
MBMary G. Boyle
Mary G. Boyle
PURPOSE: The variation in reported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of pretreatment patient characteristics. We hypothesized that a prognostic factor–based model of survival among patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy could account for such differences and help guide clinical trial design and interpretation. PATIENTS AND METHODS: A database of 203 patients with unresectable or metastatic TCC was retrospectively subjected to a multivariate regression analysis to determine which patient characteristics had independent prognostic significance for survival. Patients were assigned to three risk categories depending on the number of unfavorable characteristics. Patient selection in phase II studies was addressed by developing a table of expected median survival for patient cohorts that had varying proportions of patients from the three risk categories. RESULTS: Two factors had independent prognosis: Karnofsky performance status (KPS) less than 80% and visceral (lung, liver, or bone) metastasis. Median survival times for patients who had zero, one, or two risk factors were 33, 13.4, and 9.3 months, respectively (P = .0001). The median survival time of patient cohorts could vary from 9 to 26 months simply by altering the proportion of patients from different risk categories. CONCLUSION: The presence of baseline KPS less than 80% or visceral metastasis has an impact on survival. Reporting the proportion of patients with zero, one, and two risk factors will facilitate understanding of the relevance of the median survival in phase II trials. Phase III trials should stratify patients according to the number of risk factors to avoid imbalance in treatment arms.

1 May 2007 in Nature
Verified
Journal Article
Closed access
PDF file
BPBroad Institute Genome Sequencing Platform
Broad Institute Genome Sequencing Platform
TMTarjei S. Mikkelsen
Tarjei S. Mikkelsen
BTBroad Institute Whole Genome Assembly Team
Broad Institute Whole Genome Assembly Team
MWMatthew J. Wakefield
Matthew J. Wakefield
BABronwen Aken
Bronwen Aken
KLKerstin Lindblad-Toh
Kerstin Lindblad-Toh

20 April 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
HSHoward D. Strickler
Howard D. Strickler
RBRobert D. Burk
Robert D. Burk
MFMelissa Fazzari
Melissa Fazzari
KAKathryn Anastos
Kathryn Anastos
HMHoward Minkoff
Howard Minkoff
JPJoel M. Palefsky
Joel M. Palefsky
Background: Little is known in human immunodeficiency virus (HIV)–positive women about how the combination of plasma HIV RNA level and CD4 + T-cell count is associated with the natural history of human papillomavirus (HPV) infection or about HPV reactivation—whether it occurs and with what frequency in HIV-positive women. Methods: HIV-positive (n = 1848) and -negative (n = 514) women were assessed at semiannual visits (total person-years = 5661) for cervicovaginal HPV with polymerase chain reaction assays and for squamous intraepithelial lesions (SILs) by Pap smear. We studied the prevalent detection of HPV and SILs with generalized estimating equations and the incident detection and persistence of HPV and SILs with multivariable Cox models. All statistical tests were two-sided. Results: We observed a strong interaction between the associations of CD4 + and plasma HIV RNA strata with both prevalent ( Pinteraction = .002) and incident ( Pinteraction = .001) detection of HPV. Indeed, the hazard ratio for incident HPV detection peaked between 4.0 and 5.0, with either a CD4 + count of less than 200 cells per mm 3 or an HIV RNA level of more than 100 000 copies per mL. Although incident HPV detection in all women was associated with the number of recent sex partners ( Ptrend <.001), 22% of sexually inactive HIV-positive women with a CD4 + count of less than 200 cells/mm 3 also had at least one incidently detected HPV type. The association between CD4 + /HIV RNA strata and HPV persistence was statistically significantly smaller ( P <.001) than for incident HPV detection. SIL prevalence, incident detection, and persistence had similar associations with CD4 + /HIV RNA strata as HPV (above). Conclusion: In HIV-positive women, plasma HIV RNA level and CD4 + count in combination appear to have a strong and statistically interactive association with incident detection of HPV, some of which may reflect HPV reactivation (e.g., in sexually inactive women). The more moderate association between HIV coinfection and HPV persistence could partly explain why cervical cancer rates have not reached more epidemic proportions in HIV-positive women.

1 June 2010 in Cell
Verified
Journal Article
Closed access
JCJennifer C. Chow
Jennifer C. Chow
Constance CiaudoConstance Ciaudo
Constance Ciaudo
MFMelissa J. Fazzari
Melissa J. Fazzari
NMNathan Mise
Nathan Mise
NSNicolas Servant
Nicolas Servant
EHEdith Heard
Edith Heard

29 June 2006 in Genome Research
Verified
Journal Article
Closed access
PDF file
BKBatbayar Khulan
Batbayar Khulan
RTReid F. Thompson
Reid F. Thompson
KYKenny Ye
Kenny Ye
MFMelissa J. Fazzari
Melissa J. Fazzari
MSMasako Suzuki
Masako Suzuki
JGJohn M. Greally
John M. Greally
The distribution of cytosine methylation in 6.2 Mb of the mouse genome was tested using cohybridization of genomic representations from a methylation-sensitive restriction enzyme and its methylation-insensitive isoschizomer. This assay, termed HELP (HpaII tiny fragment Enrichment by Ligation-mediated PCR), allows both intragenomic profiling and intergenomic comparisons of cytosine methylation. The intragenomic profile shows most of the genome to be contiguous methylated sequence with occasional clusters of hypomethylated loci, usually but not exclusively at promoters and CpG islands. Intergenomic comparison found marked differences in cytosine methylation between spermatogenic and brain cells, identifying 223 new candidate tissue-specific differentially methylated regions (T-DMRs). Bisulfite pyrosequencing confirmed the four candidates tested to be T-DMRs, while quantitative RT-PCR for two genes with T-DMRs located at their promoters showed the HELP data to be correlated with gene activity at these loci. The HELP assay is robust, quantitative, and accurate and is providing new insights into the distribution and dynamic nature of cytosine methylation in the genome.

1 June 2004 in Nature Reviews Genetics
Verified
Journal Article
Closed access
MFMelissa J. Fazzari
Melissa J. Fazzari
JGJohn M. Greally
John M. Greally